Nuvalent
Biotechnology
Nuvalent is a clinical-stage biopharmaceutical company developing precisely targeted kinase-inhibitor therapies for patients with cancer, with parallel lead programs in ROS1-positive and ALK-positive non-small cell lung cancer (NSCLC). Using structure-based drug design, it develops small molecules designed to overcome kinase resistance and improve target selectivity.
- Zidesamtinib (ROS1 inhibitor for ROS1-positive NSCLC)
- Neladalkib (ALK inhibitor for ALK-positive NSCLC; NDA accepted with FDA Priority Review, PDUFA date November 27, 2026)
- Pipeline of multiple discovery-stage research programs
Open roles at Nuvalent
0 matching roles
No company roles match these filters
Remove a restriction to see more roles at this company, or save this search for later.